|
Announcements
BIOPORTO DIAGNOSTICS SELECTS CLINIVATION WORLDVIEW®
Leading developer of antibodies and antibody-based products selects clinivation WorldView® as their enterprise solution for on-demand global regulatory intelligence.
Natick, MA, October 10, 2008
- clinivation, Inc. announced today that BioPorto Diagnostics has selected the clinivation WorldView® enterprise solution for On-Demand Global Regulatory Intelligence.
"BioPorto is an innovative global leader in antibody research, and we are pleased that they have chosen clinivation WorldView® for comprehensive, authoritative, and up-to-date global regulatory intelligence,” said Richard Morroney, R.A.C., C.Q.A., clinivation's Vice President of Quality and Regulatory Solutions.
About clinivation WorldView® On-Demand Global Regulatory Intelligence
Clinivation WorldView® is the medical device and diagnostic industry's most comprehensive, authoritative, and up-to-date enterprise solution for On-Demand Global Regulatory Intelligence. Providing clear, step-by-step market clearance regulations, processes, and guidance for >99% of the world markets, only clinivation WorldView® delivers tried-and-true intelligence from certified, practicing professionals with real-world experience.
About BioPorto Diagnostics
Headquartered in Denmark, BioPorto Diagnostics develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. BioPorto's developments include a test (NGAL) to diagnose and monitor acute kidney damage. BioPorto's strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases.
For more information, please visit www.antibodyshop.com.
About clinivation, Inc.
Clinivation is the leading provider of integrated solutions that enable global market clearance. Guided by our singular vision - "Excellence in Market Clearance" - clinivation accelerates the entire market clearance cycle to advance new worldwide revenue and achieve new milestones of enterprise value.
Used in over 100,000 product registrations by more than 100 companies worldwide, clinivation's end-to-end technology and services deliver on our vision by eliminating revenue traps from global market clearance operations, increasing process velocity with on-demand regulatory intelligence, automating clearance-driven business controls, simplifying content unification into market clearance applications, aligning quality systems with global market clearance priorities, streamlining clinical development with clearance-focused trials, and enabling management with key performance indicators for continuous improvement and effective governance.
The world's leading medical device, diagnostics, hospital supply, and dental supply companies select clinivation because of our medtech industry focus and our unique, integrated solutions that seamlessly adapt to existing business processes and enterprise infrastructure- without the need to write custom code.
Our core brands include the clinivation Global® xi market clearance platform, clinivation WorldView® on-demand regulatory intelligence, and clinivation Clinical Suite® and clinivation Registry Suite® electronic data capture and clinical data management software.
Founded in 1999, the company is headquartered in Natick, Massachusetts, with regional offices in North America and Asia.
Visit clinivation online at www.clinivation.com
For further information:
For more information on clinivation's integrated solutions that enable global market clearance, please click here or call us at 508.655.6560. |
